The only trial that gets a population to roughly 50 pounds and reports how long it took is SURMOUNT-4: 670 adults with obesity and no diabetes went from a mean body weight of 107.3 kg to a mean of 85.2 kg across a 36-week lead-in on the maximum tolerated dose of tirzepatide, 10 mg or 15 mg weekly. That is 22.1 kg, or about 49 lb, in roughly eight months (PMID 38078870).
No trial sets out to measure time-to-50-pounds, so every other answer is arithmetic performed on published curves. The arithmetic is worth doing carefully, because 50 lb means something completely different depending on what you weigh when you start, and because the drug and the dose change the timeline by months.
- Tirzepatide at 10 mg or 15 mg took a mean 236 lb down by about 49 lb in 36 weeks in SURMOUNT-4's open-label lead-in.
- Semaglutide 2.4 mg is slower: STEP 1 averaged 15.3 kg, about 34 lb, over 68 weeks, so 50 lb is above average at that dose unless you start heavy.
- 50 lb is 14.3% of 350 lb and 25% of 200 lb. The first is near the semaglutide mean; the second is beyond every published mean.
- Ozempic's maximum dose is 2 mg, and its own trial at that dose recorded 6.9 kg over 40 weeks. The 50 lb figures do not come from it.
Convert the target before you time it
Trials report percentages, not pounds, so the first step is turning 50 lb into the percentage your own body would have to lose. The same 50 lb sits in a completely different part of the published distribution depending on where you start.
| Starting weight | 50 lb as a share of it | Where that sits in the trials |
|---|---|---|
| 400 lb | 12.5% | Below the STEP 1 mean of 14.9% on semaglutide 2.4 mg |
| 350 lb | 14.3% | Right at the STEP 1 mean |
| 300 lb | 16.7% | Above semaglutide's mean, below tirzepatide's |
| 250 lb | 20.0% | Near the SURMOUNT-1 mean of 20.9% at 15 mg |
| 220 lb | 22.7% | Above every published trial mean |
| 200 lb | 25.0% | Four percentage points above the highest trial mean |
| 180 lb | 27.8% | No trial reports a mean anywhere near this |
This is why two people can read the same trial and get honest answers that differ by a year. At 350 lb, 50 lb is roughly what the average semaglutide participant did in 68 weeks. At 200 lb it is more than any trial mean, and the question stops being how long and becomes whether.
What each trial reached, and when
Four trials put a population within sight of 50 lb, and a fifth shows what the dose most people ask about actually did. Each row names the drug and dose, whether participants had type 2 diabetes, the duration, and the mean change in kilograms as well as percent, because the kilogram figure is what converts to pounds without assuming a starting weight.
| Trial | Drug and dose | Population | Duration | Mean loss |
|---|---|---|---|---|
| SURMOUNT-4 lead-in (PMID 38078870) | Tirzepatide 10 or 15 mg, max tolerated | Obesity or overweight, no diabetes | 36 weeks | -20.9%; 107.3 kg to 85.2 kg, about 49 lb |
| SURMOUNT-1 (PMID 35658024) | Tirzepatide 15 mg | Obesity or overweight, no diabetes | 72 weeks | -20.9% from a mean 104.8 kg, about 48 lb |
| STEP UP (PMID 40961952) | Semaglutide 7.2 mg | Obesity, no diabetes | 72 weeks | -18.7% from a mean 113.0 kg, about 47 lb |
| STEP 1 (PMID 33567185) | Semaglutide 2.4 mg | Overweight or obesity, no diabetes | 68 weeks | -14.9%, or -15.3 kg, about 34 lb |
| SUSTAIN FORTE (PMID 34293304) | Semaglutide 2.0 mg | Type 2 diabetes | 40 weeks | -6.9 kg, about 15 lb |
The first two rows share a number and that coincidence is instructive. SURMOUNT-4 reached 20.9% in 36 weeks; SURMOUNT-1 reached 20.9% in 72. The difference is who was being measured. SURMOUNT-4's figure describes the people who got through an open-label lead-in on the highest dose they could tolerate, so it excludes anyone who dropped out early, while SURMOUNT-1's treatment-regimen estimand counts everyone randomised including those who stopped. The honest reading is that 36 weeks is the best case for a tolerating participant and 72 weeks is the population average.
The bottom row is the one worth reading twice if you arrived here searching for Ozempic. Ozempic's maximum labelled dose is 2 mg, and SUSTAIN FORTE tested exactly that dose for 40 weeks in adults with type 2 diabetes, recording a mean 6.9 kg. Fifty pounds is not an Ozempic average at any duration in the published record. We break down what each product's own trials measured in how much weight you can lose on Zepbound and across all the GLP-1 averages.
The first five months are the slow part
A 36-week or 72-week endpoint hides the shape of the curve, and the shape is what makes month-by-month predictions wrong. Both drugs spend the opening months escalating: SURMOUNT-1 included a 20-week dose-escalation period before anyone was on 15 mg, and the semaglutide labels build to 2.4 mg in four-week steps.
Two measurements catch the curve mid-flight. STEP 4's 20-week run-in on semaglutide produced a mean loss of 10.6% of body weight before randomisation (PMID 33755728). And in a retrospective cohort of 175 patients prescribed semaglutide 1.7 mg or 2.4 mg at a weight management clinic, mean loss was 5.9% at three months and 10.9% at six (PMID 36121652).
Put against a 250 lb starting weight, 10.9% at six months is about 27 lb. That is a little over half of 50 lb at the halfway point of a year, and the back half of the year is slower than the front half, not faster. Expecting a straight line from month three is the single most common way these timelines get misjudged, and what happens when the line bends is covered in our piece on the GLP-1 weight loss plateau.
How many people actually get there
Averages decide the timeline; distributions decide whether it applies to you. SURMOUNT-1 reported that 57% of the tirzepatide 15 mg group and 50% of the 10 mg group lost 20% or more of body weight by week 72, against 3% on placebo. STEP 1 did not publish a 20% threshold, but 50.5% of its semaglutide group reached 15% or more and 69.1% reached 10% or more by week 68.
Clinic data is less generous than trial data. Of the 102 patients followed to six months in that retrospective cohort, 87.3% had lost 5% or more, 54.9% had lost 10% or more, 23.5% had lost 15% or more and 7.8% had lost 20% or more. Six months is early for a 20% figure, but the gap between a trial population and a clinic population is real, and it is the clinic number most readers belong to.
Type 2 diabetes moves these odds more than almost anything else. In the same cohort, six-month loss averaged 7.2% with type 2 diabetes against 11.8% without.
Turn 50 pounds into a percentage and a timeline
Enter your starting weight and the calculator shows what each trial's percentage works out to in pounds, and roughly when.
A target in pounds and a trial reported in percent are not the same unit, and converting between them by hand is where most of the error creeps in. The GLP-1 weight loss calculator does that conversion from your own starting weight, which turns a question like fifty pounds into a specific percentage you can check against the four trials above.
Reaching 50 pounds and keeping it are separate questions
SURMOUNT-4 was designed to test the second one. After the 36-week lead-in that produced the roughly 49 lb figure, 670 participants were randomly assigned to continue tirzepatide or switch to placebo for another 52 weeks. From week 36 to week 88, the continuing group lost a further 5.5% on average while the placebo group regained 14.0%, a difference of 19.4 percentage points.
The maintenance figures are starker than the means. Of those who continued, 89.5% kept at least 80% of the weight they had lost during the lead-in, against 16.6% of those switched to placebo. Over the full 88 weeks, mean reduction was 25.3% with tirzepatide and 9.9% with placebo. What the equivalent withdrawal looks like on semaglutide is covered in stopping a GLP-1 and weight regain.
So the realistic answer to how long it takes to lose 50 pounds has two halves. On tirzepatide at a tolerated 10 mg or 15 mg, somewhere between eight and seventeen months if you start near 250 lb, and longer or not at all if you start much lighter. On semaglutide 2.4 mg, sixty-eight weeks of treatment took the average STEP 1 participant to about 34 lb, so 50 lb needs either a heavier starting weight or an above-average response. And in both cases the published data says the weight comes back when the drug stops, which makes the timeline a question about treatment rather than about a finish line.
FAQ
How long does it take to lose 50 pounds on a GLP-1?
The closest measured figure is SURMOUNT-4, where 670 adults with obesity and no diabetes went from a mean 107.3 kg to a mean 85.2 kg over a 36-week open-label lead-in on the maximum tolerated dose of tirzepatide, 10 mg or 15 mg. That is 22.1 kg, about 49 lb, in roughly eight months (PMID 38078870). On semaglutide 2.4 mg the pace is slower: STEP 1 recorded a mean loss of 15.3 kg, about 34 lb, over 68 weeks (PMID 33567185).
How long does it take to lose 50 pounds on Ozempic?
No Ozempic trial reports a 50 lb average, and the dose is the reason. Ozempic's maximum labelled dose is 2 mg, and in SUSTAIN FORTE that dose produced a mean loss of 6.9 kg, about 15 lb, over 40 weeks in adults with type 2 diabetes (PMID 34293304). The percentages people associate with 50 lb come from semaglutide 2.4 mg, which is a Wegovy dose, or from tirzepatide.
Is 50 pounds a realistic target?
It depends almost entirely on your starting weight, because 50 lb is a different percentage from 200 lb than from 350 lb. At 350 lb it is 14.3%, close to the 14.9% STEP 1 average on semaglutide 2.4 mg. At 200 lb it is 25%, which exceeds every mean in the published trials and sits in the upper tail of the tirzepatide results.
How fast is the weight lost in the first few months?
Front-loaded, but slower than the endpoint suggests, because the first four to five months are spent escalating the dose. STEP 4 reported a mean loss of 10.6% of body weight across a 20-week semaglutide run-in (PMID 33755728), and a real-world cohort of 175 patients on semaglutide averaged 5.9% at three months and 10.9% at six months (PMID 36121652).
What share of people actually reach 20% or more?
In SURMOUNT-1, 57% of the tirzepatide 15 mg group and 50% of the 10 mg group lost 20% or more of body weight by week 72, against 3% on placebo (PMID 35658024). STEP 1 reported up to a 15% threshold, which 50.5% of the semaglutide 2.4 mg group reached by week 68. In the real-world cohort, only 8 of the 102 patients followed to six months, 7.8%, had reached 20%.
Does the weight stay off once you get there?
SURMOUNT-4 is the trial that tested this directly. After the 36-week lead-in, participants were randomised to continue tirzepatide or switch to placebo for 52 weeks. Those who continued lost a further 5.5% on average, while the placebo group regained 14.0%, and 89.5% of the continuing group kept at least 80% of the lead-in loss against 16.6% on placebo.
Sources
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728
- Wharton S, Freitas P, Hjelmesaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. PMID: 40961952
- Frias JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574. PMID: 34293304
- Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982. PMID: 36121652
This article is for information only and is not medical advice. Weight loss targets, suitability and any change to treatment are decisions for your prescriber.